Back Back
Cell No. : Cell Name
RCB0452 : HTC/C3  update : 2022/03/15
CommentSecretes IL-1,TGFα,GM-CSF but not thyroglobulin
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
Thyroid Group Mori Sugawa Clinic

606 Kikkoya-machi, Nakagyou-ku, Kyoto 604-8105 Japan
Fax. +81-75-255-2002
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Sugawa, Hideo
Originator Sugawa, H. & Inoue, D.
Year of deposit 1989
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 44 years
Tissue thyroid
Disease name thryroid carcinoma
Metastatic ability Yes
Classification cancer
Year of origin 1986
Memo_1 Mycoplasma was eliminated with MC-210.
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_1295
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 60-243(50) : /62(2),63(3),64(2),66(1),69(3),102(3)/
STR(human) OK
Reference information Reference 3
User's Publication 8

To topTop
202  Sugawa H, Akamizu T, Kosugi S, Ueda Y, Ohta C, Okuda J, Mori T.  Presence of heterogeneous thyroid-stimulating antibodies in sera from individual Graves' patients as shown by synthesized thyrotropin receptor peptide application: evidence showing two independent epitopes and a possible recognition of two epitopic regions by one antibody molecule  Eur J Endocrinol  1995  33(3):283-93  PubMed ID: 7581943   DOI: 10.1530/eje.0.1330283
201  Sugawa H, Miyamoto M, Higuchi K, Smith E, Mori T, Imura H.  Production and properties of novel human thyroid cancer specific monoclonal antibodies  Biochem Biophys Res Commun  1992  187(1):404-12  PubMed ID: 1520327   DOI: 10.1016/s0006-291x(05)81507-4
3683  Enomoto T, Sugawa H, Inoue D, Miyamoto M, Kosugi S, Takahashi T, Kitamura N, Yamamoto I, Konishi J, Mori T, et al.  Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines.  Cancer  1990  65(9):1971-9  PubMed ID: 2196988   DOI: 10.1002/1097-0142(19900501)65:9<1971::aid-cncr2820650916>;2-v

To topTop
User's Publication
16320  Kawamura Y, Saijo K, Imai H, Ishioka C.  Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells  Cancer Sci  2021  112(11):4711-4721  PubMed ID: 34328666   DOI: 10.1111/cas.15095
16175  Bonaldi E, Gargiuli C, De Cecco L, Micali A, Rizzetti MG, Greco A, Borrello MG, Minna E.  BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells  Int J Mol Sci  2021  22(11):5744  PubMed ID: 34072194   DOI: 10.3390/ijms22115744
11303  Cetti E, Di Marco T, Mauro G, Mazzoni M, Lecis D, Minna E, Gioiosa L, Brich S, Pagliardini S, Borrello MG, Pruneri G, Anania MC, Greco A.  Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.  Cancer Lett.  2019    PubMed ID: 30445205   DOI: 10.1016/j.canlet.2018.11.010
14757  Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Sone M, Yasoda A, Inagaki N.  Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study  Thyroid  2017  27(7):894-901  PubMed ID: 28537531   DOI: 10.1089/thy.2016.0562
7264  Varinelli L, Caccia D, Volpi CC, Caccia C, De Bortoli M, Taverna E, Gualeni AV, Leoni V, Gloghini A, Manenti G, Bongarzone I.  4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.  Endocr. Relat. Cancer  2015  22:759-75  PubMed ID: 26206776   DOI: 10.1530/ERC-15-0299
14995  Anania M, Gasparri F, Cetti E, Fraietta I, Todoerti K, Miranda C, Mazzoni M, Re C, Colombo R, Ukmar G, Camisasca S, Pagliardini S, Pierotti M, Neri A, Galvani A, Greco A.  Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening  Oncotarget   2015  6(33):34629-48  PubMed ID: 26431489   DOI: 10.18632/oncotarget.5282
14429  S Fujieda, C Sugimoto, M Seki, H Sunaga, H Saito  CD40 stimulation inhibits cell growth and Fas-mediated apoptosis in a thyroid cancer cell line  ncol Res  1998  10(9):433-9  PubMed ID: 10223618  
1668  Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.  Cancer Res  1992  52:5061-4  PubMed ID: 1516062  

Back Back Return Top Page